Obesity Clinical Trials in Dallas, Texas
21 studies are recruiting for obesity in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Velocity Clinical Research - Dallas /ID# 282734, Dallas, Texas
- Locations
- 45 in total
- Run by
- AbbVie
-
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…
- Stage
- Phase 3
- Ages
- 18 to 99
- Site
- Cedar Health Research, LLC, Dallas, Texas
- Locations
- 657 in total
- Run by
- Amgen
-
Spinal Cord Injury Model Systems (SCIMS) - Education Module
The purpose of this study is to find out if receiving education regarding increased risks of cardiometabolic disease helps subjects understand these risks and how these risks participants' health.
- Stage
- Not phased
- Ages
- 18 to 70
- Site
- Baylor Scott & White Institute for Research, Dallas, Texas
- Locations
- 3 in total
- Run by
- University of Miami
-
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be u…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Cedar Health Research, Dallas, Texas
- Locations
- 62 in total
- Run by
- Novo Nordisk A/S
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Velocity Clinical Research, Dallas, Dallas, Texas
- Locations
- 56 in total
- Run by
- Eli Lilly and Company
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Mercy Family Clinic, Dallas, Texas
- Locations
- 42 in total
- Run by
- Eli Lilly and Company
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Velocity Clinical Research, Dallas, Dallas, Texas
- Locations
- 157 in total
- Run by
- Eli Lilly and Company
-
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- UT Southwestern Medical Center, Dallas, Texas
- Locations
- 187 in total
- Run by
- Eli Lilly and Company
-
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- UT Southwestern Med Center, Dallas, Texas
- Locations
- 74 in total
- Run by
- Novo Nordisk A/S
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic ner…
- Stage
- EARLY_Phase 1
- Ages
- 18 to 55
- Site
- University of Texas Southwestern Medical Center, Dallas, Texas
- Run by
- University of Texas Southwestern Medical Center
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
- Stage
- Phase 3
- Ages
- 45 to 99
- Site
- Thyroid Endocrinology and Diabetes, Dallas, Texas
- Locations
- 783 in total
- Run by
- Amgen
-
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).
- Stage
- Phase 3
- Ages
- 18 to 99
- Site
- Cedar Health Research, LLC, Dallas, Texas
- Locations
- 87 in total
- Run by
- Amgen
-
Effects of Obesity in the Aged
The overall objective of this application is to investigate the effects of obesity on lung function, exercise tolerance, and DOE in older obese adults as compared with older adults without obesity, using a novel probe for mechanically unloading the thorax at rest and during exercise. The investigat…
- Stage
- Not phased
- Ages
- 65 to 75
- Site
- Institute for Exercise and Environmental Medicine, UT Southwestern and Texas Health Resources, Dallas, Texas
- Run by
- University of Texas Southwestern Medical Center
-
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Velocity Clin Res, Dallas, Dallas, Texas
- Locations
- 303 in total
- Run by
- Novo Nordisk A/S
-
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Velocity Clinical Research, Dallas, Dallas, Texas
- Locations
- 162 in total
- Run by
- Eli Lilly and Company
-
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …
- Stage
- Phase 2
- Ages
- 7 to 25
- Site
- University of Texas, Southwestern, Dallas, Texas
- Locations
- 16 in total
- Run by
- Etan Orgel
-
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Renal Disease Research Institute, Dallas, Texas
- Locations
- 838 in total
- Run by
- Novo Nordisk A/S
-
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the tr…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Mercy Family Clinic, Dallas, Texas
- Locations
- 81 in total
- Run by
- Novo Nordisk A/S
-
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- FutureSearch Trials of Dallas, Dallas, Texas
- Locations
- 40 in total
- Run by
- Eli Lilly and Company
-
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) …
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Velocity Clinical Res-Dallas, Dallas, Texas
- Locations
- 72 in total
- Run by
- Novo Nordisk A/S
-
Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF
The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contrib…
- Stage
- Not phased
- Ages
- 55 to 90
- Site
- UT Southwestern Medical Center, Dallas, Texas
- Run by
- University of Texas Southwestern Medical Center
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.